Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review
Annals of Translational Medicine · 2023-08 · 11 (10) · 358-358
DOI: 10.21037/atm-22-4444 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Annals of Translational Medicine, 2023-08. Verfasst von Molly S C Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China. Die Arbeit wurde bisher 56-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.
- Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China.
Zitieren
APA
Li, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023). Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review. Annals of Translational Medicine, 11(10), 358-358. https://doi.org/10.21037/atm-22-4444
Vancouver
Li MSC, Mok KKS, Mok TSK. Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review. Annals of Translational Medicine. 2023;11(10):358-358. doi:10.21037/atm-22-4444
BibTeX
@article{Li2023,
author = {Li, Molly S C and Mok, Kevin K S and Mok, Tony S K},
title = {Developments in targeted therapy & immunotherapy—how non-small cell lung cancer management will change in the next decade: a narrative review},
journal = {Annals of Translational Medicine},
year = {2023},
volume = {11},
number = {10},
pages = {358--358},
doi = {10.21037/atm-22-4444}
}
EUVIMED